Discontinuation of Levemir FlexPen and Levemir vials
Review preferred covered alternatives
Drug manufacturer Novo Nordisk released a notice on Nov. 8, 2023, announcing that they would be discontinuing 2 of their brand products; Levemir® FlexPen® and Levemir® vials. According to the announcement, supply disruptions of Levemir FlexPen are expected to start mid-January 2024, lasting up until the discontinuation of FlexPen on April 1, 2024. Levemir vials will be discontinued on Dec. 31, 2024.
Preferred covered alternatives
We have identified preferred covered alternatives to help ensure your patients with UnitedHealthcare benefit plans continue to have access to a covered long-acting insulin to treat diabetes.
Refer to the table below to determine if any of the preferred covered alternatives are suitable options for your affected patients. You can also view covered alternatives by using PreCheck MyScript via most electronic medical records’ real-time benefit check functionality, or the UnitedHealthcare Provider Portal.
| UnitedHealthcare plan | Preferred covered long-acting insulins |
|---|---|
| UnitedHealthcare commercial plans | For plans providing coverage: Lantus®, Lantus SoloStar®, Toujeo® SoloStar®, Toujeo® Max SoloStar® |
| Individual Exchange plans, also referred to as UnitedHealthcare Individual & Family ACA Marketplace plans | Basaglar®, Rezvoglar™, Tresiba®, and insulin degludec (Tresiba Authorized Generic) |
| UnitedHealthcare Community plans | View state-specific drug lists for preferred covered long-acting insulins |
| Individual and Group UnitedHealthcare® Medicare Advantage and stand-alone Part D plans | For plans that currently cover Levemir: Lantus, Lantus SoloStar, Toujeo SoloStar, Toujeo Max SoloStar, Tresiba, and Tresiba® FlexTouch® For plans that currently do not cover Levemir: Lantus, Lantus SoloStar, Toujeo SoloStar, and Toujeo Max SoloStar |
Questions? We're here to help
Connect with us through chat 24/7 in the UnitedHealthcare Provider Portal. For additional contact information, visit our Contact us page.
PCA-1-23-04112-Clinical-NN-12202023
